Genentech Alzheimer’s drug misses goals in studies
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer’s disease, but showed some promise in the least-impaired participants who received a higher dose.
Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people.
“We’re very encouraged” by the hint of benefit for patients with milder dementia and will talk with regulators about next steps for the drug, crenezumab (cruh-NEZ-oo-mab), said a Genentech scientist, Dr. Carole Ho. The results fit with other evidence suggesting that treating earlier in the course of the disease is better, she said.
Results were revealed Wednesday at the Alzheimer’s Association International Conference in Copenhagen.
They are the latest mixed bag on treatments aimed at clearing away the sticky amyloid plaques clogging Alzheimer’s patients’ brains. About 35 million people worldwide have Alzheimer’s, the most common form of dementia. There is no cure and current treatments only temporarily ease symptoms.
Last year, an Eli Lilly & Co. medicine, solanezumab, that also sought to clear away amyloid missed main goals in two studies but combined results suggested it might help people with milder disease. It’s in further study now. Before that, bapineuzumab, a similar drug being developed by Pfizer Inc. and Johnson & Johnson, showed promise in mid-stage testing but flopped in larger, more definitive trials.